RB1 and pancreatic endocrine carcinoma: Pancreatic NECs account for 7.5% of PanNENs, display recurrent TP53 and RB1 mutations, and have a dismal outcome, similar to other NECs of the gastroenteric tract (27, 40, 96, 97).